In 2015, we generated net sales of $7.477 billion, reflecting an increase of $97 million compared to 2014, despite unfavorable impacts from foreign currency fluctuations. Our cash generated from operations continues to be a significant source of funds for investing in our growth, including acquisitions and strategic alliances, managing contingencies, and reducing debt levels. We believe our investment-grade credit profile reflects the size and diversity of our product portfolio, our leading share position in several of our served markets, our strong cash flow, and our solid financial fundamentals. We are seeking to expand our presence and strengthen relationships in emerging markets to grow net sales and market share, with our emerging markets revenue growing two percent in 2015. The acquisition of the American Medical Systems male urology portfolio is being integrated with our urology and women's health business, enhancing our ability to offer a more complete portfolio of solutions to treat challenging vascular conditions. Our restructuring initiatives are aimed at improving operational effectiveness and efficiency while preserving our ability to invest in research and development projects and other programs that drive growth. We monitor the dynamics of the economy and healthcare industry to assess opportunities for improved operational flexibility and resource allocation. Our investments in infrastructure and technology are designed to maximize opportunities and support our strategic imperatives for global expansion. We assess our internal control over financial reporting to ensure reliability and compliance with generally accepted accounting principles, which includes maintaining adequate internal control processes to support our operational goals. Our commitment to advancing medical technologies is reflected in our increased research and development expenses, which are essential for maintaining a healthy pipeline of new products that contribute to profitable sales growth. The integration of acquired technologies and products is crucial for enhancing our market positioning and operational capabilities. We recognize the importance of mobilizing and deploying IT-based resources in combination with leveraging other resources and capabilities to transform our firm into a competitive force. Our strategic management practices focus on aligning technology capabilities with business needs to enhance performance and support decision-making processes. We believe that our less-invasive products and technologies generate favorable clinical outcomes and value, which are critical in demonstrating value to customers and stakeholders. The ongoing assessment of our operational performance and investment decisions is vital for adapting to market dynamics and ensuring long-term success. We are committed to leveraging our IT capabilities to support business innovation and transformation, which are essential for achieving our organizational goals and enhancing overall firm performance.